DB:30O

Stock Analysis Report

Executive Summary

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan.

Risk Analysis

Earnings have declined by -8.03% per year over past 5 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year

+ 1 more risk


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has OncoTherapy Science's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 30O's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.7%

30O

-1.0%

DE Biotechs

1.7%

DE Market


1 Year Return

-31.1%

30O

6.2%

DE Biotechs

15.0%

DE Market

Return vs Industry: 30O underperformed the German Biotechs industry which returned 6.2% over the past year.

Return vs Market: 30O underperformed the German Market which returned 15% over the past year.


Shareholder returns

30OIndustryMarket
7 Day-4.7%-1.0%1.7%
30 Day-18.9%-2.3%0.8%
90 Day-4.1%7.8%3.7%
1 Year-31.1%-31.1%6.4%6.2%18.5%15.0%
3 Year-67.6%-67.6%49.0%47.3%17.1%6.9%
5 Year-76.2%-76.2%12.6%10.3%24.3%7.3%

Price Volatility Vs. Market

How volatile is OncoTherapy Science's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is OncoTherapy Science undervalued compared to its fair value and its price relative to the market?

3.15x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 30O's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 30O's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 30O is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 30O is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 30O's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 30O is good value based on its PB Ratio (3.1x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is OncoTherapy Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OncoTherapy Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has OncoTherapy Science performed over the past 5 years?

-8.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 30O is currently unprofitable.

Growing Profit Margin: 30O is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 30O is unprofitable, and losses have increased over the past 5 years at a rate of -8% per year.

Accelerating Growth: Unable to compare 30O's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 30O is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 30O has a negative Return on Equity (-63.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is OncoTherapy Science's financial position?


Financial Position Analysis

Short Term Liabilities: 30O's short term assets (¥4.6B) exceed its short term liabilities (¥267.0M).

Long Term Liabilities: 30O's short term assets (¥4.6B) exceed its long term liabilities (¥132.0M).


Debt to Equity History and Analysis

Debt Level: 30O is debt free.

Reducing Debt: 30O has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 30O has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 30O's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 30O has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 30O has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of -7.1% each year.


Next Steps

Dividend

What is OncoTherapy Science's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 30O's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 30O's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 30O's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 30O's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 30O's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average board tenure


CEO

Jae-Hyun Park 0

1.1yrs

Tenure

0

Jae-Hyun Park serves as Director at OncoTherapy Science, Inc. since June 2018 and also it's President and Chief Executive Officer since 2019. 


Board Members

NamePositionTenureCompensationOwnership
Jae-Hyun Park
President1.1yrsno datano data
Shuichi Nakatsuru
Full-Time Auditor11.7yrsno data3.32% ¥4.2m
Yuichi Komine
External Director5.4yrsno datano data
Miyako Takagi
External Auditor15.7yrsno data0.018% ¥22.4k
Toyomasa Katagiri
External Director9.7yrsno data0.014% ¥18.1k
Teruhisa Tajima
External Auditor5.4yrsno datano data
Tomoaki Fujioka
External Director5.4yrsno datano data
Su-Youn Chung
Director0yrsno datano data

5.4yrs

Average Tenure

58yo

Average Age

Experienced Board: 30O's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.5%.


Top Shareholders

Company Information

OncoTherapy Science, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OncoTherapy Science, Inc.
  • Ticker: 30O
  • Exchange: DB
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥15.165b
  • Listing Market Cap: JP¥127.403m
  • Shares outstanding: 176.33m
  • Website: https://www.oncotherapy.co.jp

Number of Employees


Location

  • OncoTherapy Science, Inc.
  • Building D
  • 11th Floor, Kanagawa Science Park
  • Kawasaki
  • Kanagawa
  • 213-0012
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4564TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYDec 2003
30ODB (Deutsche Boerse AG)YesCommon StockDEEURDec 2003

Biography

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company’s clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for soft tissue synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer’s disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/16 22:18
End of Day Share Price2020/02/14 00:00
Earnings2019/12/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.